460 related articles for article (PubMed ID: 21750419)
1. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
[TBL] [Abstract][Full Text] [Related]
2. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
[TBL] [Abstract][Full Text] [Related]
4. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
[TBL] [Abstract][Full Text] [Related]
6. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ
AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765
[TBL] [Abstract][Full Text] [Related]
7. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
[TBL] [Abstract][Full Text] [Related]
10. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
11. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
[TBL] [Abstract][Full Text] [Related]
12. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.
Kallianpur AR; Wang Q; Jia P; Hulgan T; Zhao Z; Letendre SL; Ellis RJ; Heaton RK; Franklin DR; Barnholtz-Sloan J; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Grant I;
J Infect Dis; 2016 Apr; 213(7):1065-73. PubMed ID: 26690344
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
Airoldi M; Bandera A; Trabattoni D; Tagliabue B; Arosio B; Soria A; Rainone V; Lapadula G; Annoni G; Clerici M; Gori A
Clin Dev Immunol; 2012; 2012():467154. PubMed ID: 22489249
[TBL] [Abstract][Full Text] [Related]
14. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.
Crum-Cianflone NF; Moore DJ; Letendre S; Poehlman Roediger M; Eberly L; Weintrob A; Ganesan A; Johnson E; Del Rosario R; Agan BK; Hale BR
Neurology; 2013 Jan; 80(4):371-9. PubMed ID: 23303852
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
[TBL] [Abstract][Full Text] [Related]
16. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era.
Cohen RA; Harezlak J; Schifitto G; Hana G; Clark U; Gongvatana A; Paul R; Taylor M; Thompson P; Alger J; Brown M; Zhong J; Campbell T; Singer E; Daar E; McMahon D; Tso Y; Yiannoutsos CT; Navia B
J Neurovirol; 2010 Feb; 16(1):25-32. PubMed ID: 20113183
[TBL] [Abstract][Full Text] [Related]
17. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
[TBL] [Abstract][Full Text] [Related]
18. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
[TBL] [Abstract][Full Text] [Related]
19. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.
Heaton RK; Franklin DR; Ellis RJ; McCutchan JA; Letendre SL; Leblanc S; Corkran SH; Duarte NA; Clifford DB; Woods SP; Collier AC; Marra CM; Morgello S; Mindt MR; Taylor MJ; Marcotte TD; Atkinson JH; Wolfson T; Gelman BB; McArthur JC; Simpson DM; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I; ;
J Neurovirol; 2011 Feb; 17(1):3-16. PubMed ID: 21174240
[TBL] [Abstract][Full Text] [Related]
20. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.
Tate DF; Sampat M; Harezlak J; Fiecas M; Hogan J; Dewey J; McCaffrey D; Branson D; Russell T; Conley J; Taylor M; Schifitto G; Zhong J; Daar ES; Alger J; Brown M; Singer E; Campbell T; McMahon D; Tso Y; Matesan J; Letendre S; Paulose S; Gaugh M; Tripoli C; Yiannoutsos C; Bigler ED; Cohen RA; Guttmann CR; Navia B;
J Neurovirol; 2011 Aug; 17(4):368-79. PubMed ID: 21556960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
